Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission

View Full Paper
Ask AI
Bookmark
Share

Authors

ABArielle BaimCOClaire OligKFKathryn E. Flynn

Discussion

Loading...

Member takes

Overview

Investigator-initiated trial achieves 41.9% MR4 or better in chronic myeloid leukemia patients, suggesting asciminib's potential with lowTKIs.

Key Points

  • 41.9% of patients achieved MR4 or better at 12 months, indicating the efficacy of asciminib treatment.
  • Patients received asciminib followed by lowTKI if needed, with 90.2% remaining on treatment and 12 added lowTKI.
  • Adverse events included anemia (28%), neutropenia (13%), and fatigue (26%), presenting a manageable safety profile.
  • Further analysis is needed to determine long-term outcomes and the benefits of lowTKIs in chronic myeloid leukemia.

Cite This Study

Baim et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6behttps://doi.org/10.1182/blood-2025-7311
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Asciminib in chronic myeloid leukemia: Superior efficacy and favorable safety outcomes from a systematic review and meta-analysis2025
  2. 2Asciminib as monotherapy or adjunctive therapy for chronic myeloid leukaemia in blast phase2025
  3. 3Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results2026
  4. 4A comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase2025
  5. 5Asciminib for relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and lymphoid blast crisis of chronic myeloid leukemia (LBC-CML) in Italy: A Campus ALL real life study2025